Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 200, pseudogene (RNU6-200P) is a processed pseudogene related in sequence to the functional U6 small nuclear RNA (snRNA) genes, which are essential components of the spliceosome involved in mRNA splicing[1][3][4][5]. As a pseudogene, RNU6-200P does not encode a functional snRNA and is not transcribed into a functional product. It is classified as a non-coding, non-functional genomic element and does not serve as a therapeutic or diagnostic target. Pseudogenes like RNU6-200P may be differentially expressed in certain contexts (such as cancer), but there is no evidence that this particular pseudogene is a receptor, enzyme, transporter, or other classical drug target[1][2]. Its main relevance is as a genomic marker indicating past retrotranspositional events involving U6 snRNA; there is no direct evidence of pathological or therapeutic relevance for this specific locus[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 200, pseudogene (RNU6-200P).